Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hunan Cancer Hospital
This study aims to evaluate the feasibility of plasma ctDNA mutation in guiding late-line treatment for late-stage metastatic breast cancer patients. Meanwhile, this study tries to evaluate the curative effect of ctDNA subtype-guided late-line therapy.
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Recent progression of TNBC after multiple lines of chemotherapy or of HR+ or HER2+ MBC after multiple lines of endocrine or targeted therapy;
No available recommendation for the next treatment regimen;
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
An updated, available pathological HR/HER2 status for metastasis;
According to RECIST 1.1 standard, there should be at least one measurable target lesion;
The expected survival time is \> 3 months;
Those aged 18-70 years old;
Liver and kidney function and blood routine test meet the following conditions: Neutrophil \> 2.0g/l, Hb \> 9g / L, PLT \> 100g / L; ALT and AST \< 2.5ULN; TBIL \< 1.5ULN; Cr \< 1.0ULN
Signing informed consent;
Those willing to accept polygenic testing.
You may not be if
Patients with multiple primary tumors;
Those who are unable to obtain blood samples;
Those with a history of immunodeficiency or organ transplantation;
Those with abnormal cardiac function or previous history of myocardial infarction or serious arrhythmia;
The researchers think it is not suitable to participate in this experiment.
Clareo Health | Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
